Big pharma doubles down on in vivo CAR-t despite setbacks

The gist

Big pharma is pouring billions into in vivo CAR-T therapies for autoimmune diseases, doubling down despite a wave of safety scares and patient deaths.

What to know

Platform Arms Race Heats Up

Big pharma is pouring billions into competing advanced therapy platforms, signaling that control over in vivo CAR-T technology is now a strategic imperative across the industry.

This is already being financed like a strategic land grab. In Vivo CAR‑T Gains Investor Interest Amid Diverse Modality Deals says the speaker is “watching big Pharma” and “seeing there’s appetite from both pharma and from investors for nvivo CAR T,” pointing to the “Colonia acquisition from Lilly, multibillion dollar acquisition,” while adding Lilly was effectively doubling down across approaches rather than making a one-off bet, a sign companies view platform control across lentiviral and RNA routes as competitively important.

The same pattern shows up across adjacent advanced-therapy platforms: AstraZeneca Invests $2B in Summit While Skipping Drug Purchase reports “AstraZeneca is investing $2B in Summit” through “convertible preferred stock” at an effective $18.36 per share, a 10% premium, for a stake plus combination-trial rights; Sanofi’s up-to-$8B milestone-backed investment in Regeneron’s long-acting antibody pipeline, including $1B upfront and up to $7B in milestones for four long-acting antibodies, shows a multibillion-dollar commitment to advanced biologics platforms adjacent to cell-therapy commercialization races; and Novo licensed HRS-1596 from Hengrui for $300M upfront and up to $2.6B total. At the 2026 Jefferies Healthcare Conference on November 17, CRISPR Therapeutics said it had “moved to this next phase of the company where we've taken both in vivo and X ex vivo approaches,” while calling Casgevy with Vertex “a multibillion dollar opportunity” after roughly $100 million in quarterly revenue.

Sources
BiotechTV - NewsBiotech Blueprint

Safety Crisis Shakes Confidence

A cascade of patient deaths and failed trials in November 2026 forced the industry to reckon with the systemic risks of autoimmune cell therapies, exposing vulnerabilities that go beyond isolated setbacks.

What changed in November 2026 was not a single bad readout but a concentration of setbacks that made autoimmune cell therapy’s safety questions harder to dismiss. BioSpace captured the turn in its Nov. 16 headline, “Deaths, failed trials and other recent setbacks in the autoimmune space,” signaling that the month had become defined by multiple negative safety and efficacy events, including deaths and failed trials, and that concern was no longer about isolated execution problems but about the modality’s broader risk profile.

That broader anxiety was sharpened by concrete patient harm already on the record: in interim Phase 1 Breakfree-2 results for CD19-directed CAR T therapy zola cel in multiple sclerosis, Bristol Myers Squibb reported “one fatal septic pneumonia case following treatment.” The Breakfree-2 update also framed autoimmune cell therapy as inherently high-risk, with safety management and trial execution highlighted as factors that can reshape programs, reinforcing why November’s cluster of disclosures and discontinuations landed as a modality-level warning sign.

Sources

Pfizer’s High-Stakes Wager

Despite recent safety scares, Pfizer’s $2.6 billion Starna deal shows major players are willing to pay top dollar for early-stage in vivo CAR-T platforms, betting on transformative potential before proof of safety.

Pfizer’s move in mid-November was the clearest sign that big pharma had not written off in vivo CAR-T for autoimmune disease, even as the field absorbed damaging news. Fierce Biotech captured that posture in a blunt headline — “Pfizer inks $2.6 B Starna deal to launch in-vivo CAR-T autoimmune programs” — and the size of the commitment mattered: a large, explicitly priced bet on a platform that still carried enough promise for a top-tier drugmaker to pay up rather than wait on the sidelines.

Yahoo Finance reported that Pfizer “signed a deal worth up to $2.6 billion with Shanghai-based Starna Therapeutics for three experimental CAR-T therapies aimed at autoimmune diseases such as lupus,” including “$330 million upfront” plus “up to $2.3 billion in milestone payments” and royalties. That structure is especially telling because the assets are still preclinical, meaning Pfizer was paying for early access to the technology itself — a foot in the door on a platform it still appears to view as potentially transformative if it can be made to work safely and reliably.

Sources

Get the stories behind the trends

Deep-dive reporting and the weekly brief, in your inbox.